Published • loading... • Updated
Switzerland-Based Novartis Breaks Ground on Radioligand Therapy Site in Denton
Summary by pcdn.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Switzerland-Based Novartis Breaks Ground on Radioligand Therapy Site in Denton
Dallas Innovates, Every Day: Here's what's new + next in North Texas. Swiss global pharmaceutical giant Novartis recently broke ground on its new radioligand therapy (RLT) manufacturing site in Denton, part of its broader $23 billion investment in U.S. manufacturing and research. When completed in 2028, the company’s first Texas‑based manufacturing facility will bring RLT medications closer to patients across the southern United States, becoming…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
